Research programme: NF-kappa B inhibitors - Scottish Biomedical

Drug Profile

Research programme: NF-kappa B inhibitors - Scottish Biomedical

Alternative Names: Research programme: anticancer therapeutics - Scottish Biomedical; SB 41947

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Scottish Biomedical
  • Class Small molecules
  • Mechanism of Action NF-kappa B inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Scotland
  • 07 Mar 2005 Preclinical trials in Cancer in Scotland (unspecified route)
  • 07 Mar 2005 SB 41947 is available for licensing or partnering (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top